Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 1;3(1):100087.
doi: 10.1016/j.imj.2024.100087. eCollection 2024 Mar.

HBsAg kinetics after 7 years of therapy with tenofovir disoproxil fumarate in a cohort of naïve patients affected by chronic hepatitis B with different genotypes

Lucio Boglione  1 , Tommaso Lupia  2 , Giacomo Stroffolini  2 , Valentina Dodaro  2 , Giovanni Di Perri  2
Affiliations

HBsAg kinetics after 7 years of therapy with tenofovir disoproxil fumarate in a cohort of naïve patients affected by chronic hepatitis B with different genotypes

Lucio Boglione et al. Infect Med (Beijing). .

Abstract

The role of different genotypes in nucleos(t)ide analogs (NAs) treatment is still debated. Previous studies conducted on special populations evidenced that the E genotype had the lower virological and serological response. This descriptive study aims to recognize the hepatitis B "s" antigen (HBsAg) decline during tenofovir disoproxil fumarate (TDF) treatment in a cohort of patient affected by chronic hepatitis B (CHB). We retrospectively included all patients with CHB treated with TDF between April 2007 and March 2012 with a duration of treatment of 7 years. Kinetics of HBsAg was determined as serological response in this cohort. We include 110 subjects; virological response was observed in all subjects with genotypes A, B, and D; in 17 patients with C genotype (94.4%) and 24 with E genotype (96%). HBeAg loss was observed in 2 patients with genotype A (50%), 3 with B (100%), 0 with C (0%), 1 with D (20%), and 1 with E genotype (25%). In multivariate analysis we observed as predictive factors of HBsAg decline the baseline level of HBsAg (OR = 1.467; 95%CI: 1.221-5.113; p = 0.017) and viral genotypes (OR = 11.218; 95%CI: 5.441-41.138; p < 0.001). This study confirmed higher HBsAg decline after 7 years of treatment in A and B genotypes, and lower in C, E, and D genotypes. However, no evidence is enough to choose a single NAs, but in special populations, as well as in genotype E, the use of TDF should be preferred to entecavir.

Keywords: Entecavir; HBsAg decline; Hepatitis B; Serological response; Tenofovir disoproxil fumarate.

PubMed Disclaimer

Figures

Fig 1
Fig. 1
Different HBsAg decline during the treatment with TDF in the study population according to viral HBV genotypes.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Yuen M.F., Chen D.S., Dusheiko G.M., et al. Hepatitis B virus infection. Nat. Rev. Dis. Primers. 2018;4:18035. doi: 10.1038/nrdp.2018.35. - DOI - PubMed
    1. European Association for the Study of the Liver Electronic address: easloffice@easloffice eu, European Association for the Study of the Liver EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021. - DOI - PubMed
    1. Erhardt A., Blondin D., Hauck K., et al. Response to interferon Alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005;54(7):1009–1013. doi: 10.1136/gut.2004.060327. - DOI - PMC - PubMed
    1. Buster E.H.C.J., Hansen B.E., Lau G.K.K., et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137(6):2002–2009. doi: 10.1053/j.gastro.2009.08.061. - DOI - PubMed
    1. Boglione L., Cusato J., Cariti G., et al. The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. J. Infect. 2014;69(1):81–87. doi: 10.1016/j.jinf.2014.02.018. - DOI - PubMed

LinkOut - more resources